Gwen Fyfe

11.8k total citations · 1 hit paper
13 papers, 9.0k citations indexed

About

Gwen Fyfe is a scholar working on Oncology, Economics and Econometrics and Statistics and Probability. According to data from OpenAlex, Gwen Fyfe has authored 13 papers receiving a total of 9.0k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 3 papers in Economics and Econometrics and 3 papers in Statistics and Probability. Recurrent topics in Gwen Fyfe's work include Health Systems, Economic Evaluations, Quality of Life (3 papers), Cancer Genomics and Diagnostics (3 papers) and Statistical Methods in Clinical Trials (3 papers). Gwen Fyfe is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (3 papers), Cancer Genomics and Diagnostics (3 papers) and Statistical Methods in Clinical Trials (3 papers). Gwen Fyfe collaborates with scholars based in United States, Australia and Switzerland. Gwen Fyfe's co-authors include Thomas H. Cartwright, Herbert I. Hurwitz, John D. Hainsworth, Eric Holmgren, Napoleone Ferrara, William Novotny, Jordan Berlin, Ari David Baron, Louis Fehrenbacher and Beth Rogers and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.

In The Last Decade

Gwen Fyfe

13 papers receiving 8.7k citations

Hit Papers

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin... 2004 2026 2011 2018 2004 2.5k 5.0k 7.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
    2004 8.4k citations Herbert I. Hurwitz, Louis Fehrenbacher et al. New England Journal of Medicine profile →

Peers

Gwen Fyfe
W. Heim United States
Napoleone Ferrara United States
Robert W. Ross United States
Lee S. Rosen United States
Mikhail Lichinitser Russia
A. Harstrick Germany
Gabriella Fontanini Italy
J. Randolph Hecht United States
Rafael G. Amado United States
Marinela Capanu United States
W. Heim United States
Gwen Fyfe
Citations per year, relative to Gwen Fyfe Gwen Fyfe (= 1×) peers W. Heim

Countries citing papers authored by Gwen Fyfe

Since Specialization
Citations

This map shows the geographic impact of Gwen Fyfe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gwen Fyfe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gwen Fyfe more than expected).

Fields of papers citing papers by Gwen Fyfe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gwen Fyfe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gwen Fyfe. The network helps show where Gwen Fyfe may publish in the future.

Co-authorship network of co-authors of Gwen Fyfe

This figure shows the co-authorship network connecting the top 25 collaborators of Gwen Fyfe. A scholar is included among the top collaborators of Gwen Fyfe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gwen Fyfe. Gwen Fyfe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Fridlyand, Jane, Lee D. Kaiser, & Gwen Fyfe. (2011). Analysis of tumor burden versus progression-free survival for Phase II decision making. Contemporary Clinical Trials. 32(3). 446–452. 12 indexed citations
2.
Abrams, Jeffrey S., et al.. (2010). Data Submission Standards and Evidence Requirements. The Oncologist. 15(5). 488–491. 9 indexed citations
3.
Bhattacharya, Suman, Gwen Fyfe, Robert J. Gray, & Daniel J. Sargent. (2009). Role of Sensitivity Analyses in Assessing Progression-Free Survival in Late-Stage Oncology Trials. Journal of Clinical Oncology. 27(35). 5958–5964. 30 indexed citations
4.
Ratain, Mark J., Rachel Humphrey, Gary Gordon, et al.. (2007). Recommended changes to oncology clinical trial design: Revolution or evolution?. European Journal of Cancer. 44(1). 8–11. 31 indexed citations
5.
Agus, David B., Michael S. Gordon, Charles Taylor, et al.. (2005). Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced Cancer. Journal of Clinical Oncology. 23(11). 2534–2543. 304 indexed citations
6.
Pegram, Mark D., Richard J. Pietras, Alex Bajamonde, Pamela Klein, & Gwen Fyfe. (2005). Targeted Therapy: Wave of the Future. Journal of Clinical Oncology. 23(8). 1776–1781. 43 indexed citations
7.
Hurwitz, Herbert I., Louis Fehrenbacher, William Novotny, et al.. (2004). Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. New England Journal of Medicine. 350(23). 2335–2342. 8433 indexed citations breakdown →
8.
Emery, Sean, William B. Capra, David A. Cooper, et al.. (2000). Pooled Analysis of 3 Randomized, Controlled Trials of Interleukin‐2 Therapy in Adult Human Immunodeficiency Virus Type 1 Disease. The Journal of Infectious Diseases. 182(2). 428–434. 86 indexed citations
9.
Jones, Dennie V., et al.. (1998). Recombinant human thrombopoietin clinical development. Stem Cells. 16(S1). 199–206. 5 indexed citations
10.
Momin, Feroze, Mark M. Zalupski, Lance K. Heilbrun, et al.. (1994). Phase II Trial of Recombinant Human Macrophage Colony-Stimulating Factor in Metastatic Soft Tissue Sarcoma. Journal of Immunotherapy. 16(3). 224–228. 1 indexed citations
11.
Janik, John E., William H. Sharfman, Dan L. Longo, et al.. (1993). Erythropoietin production. A potential marker for interleukin-2/interferon-responsive tumors. Cancer. 72(9). 2656–2659. 25 indexed citations
12.
Bukowski, Ronald M., James A. Young, Gary E. Goodman, et al.. (1993). Polyethylene glycol conjugated interleukin-2: Clinical and immunologic effects in patients with advanced renal cell carcinoma. Investigational New Drugs. 11(2-3). 211–217. 12 indexed citations
13.
McDaniel, Michael L., et al.. (1975). Effects of cytochalasins B and D on alloxan inhibition of insulin release. Biochemical and Biophysical Research Communications. 66(4). 1089–1096. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by W. Heim Breakdown of academic impact, for papers by Napoleone Ferrara Breakdown of academic impact, for papers by Robert W. Ross Breakdown of academic impact, for papers by Lee S. Rosen Breakdown of academic impact, for papers by Mikhail Lichinitser Breakdown of academic impact, for papers by A. Harstrick Breakdown of academic impact, for papers by Gabriella Fontanini Breakdown of academic impact, for papers by J. Randolph Hecht Breakdown of academic impact, for papers by Rafael G. Amado Breakdown of academic impact, for papers by Marinela Capanu
Rankless by CCL
2026